CALT שווי כולל של נכסי החברה Calliditas

The price trend visualization for Calliditas Therapeutics (CALT) total assets on GURU.Markets is 161.60, illustrating the business development of kidney pathology treatments. The company's valuation soared following a $1.3 billion acquisition by Japanese behemoth Asahi Kasei, which proved the success of Tarpeyo. An environmental development vector dictates the implementation of safe laboratory standards, while a steady influx of funds from global sales fully covers R&D costs.

Investors are assessing the potential of Calliditas Therapeutics (CALT) through a reverse calculation of total resources based on return on assets (ROA), which allows for the precise determination of equity and liabilities. By analyzing the growth of total capital and liabilities, one can see how packaging robotization and the digitalization of clinical data for kidney diseases are transforming the company's material base, confirming its ability to scale its technological infrastructure.